Pancreatic cancer is one of the hardest to treat tumor types, owing in large part to its aggressive nature and propensity for spreading to other parts of the body. Only about 10 percent of those diagnosed with pancreatic ductal adenocarcinoma (PDAC) survive for five years, and patients who have metastatic PDAC typically live less than a year even with standard chemotherapy. Newer immune-targeted therapies such as checkpoint blockade antibodies have proved to be powerful against some cancers, but they have largely failed in PDAC.
A combination of the immunotherapy nivolumab plus two chemotherapy drugs improved survival in PDAC patients who had advanced disease, according to the results of a study presented at the 2022 American Society of Clinical Oncology annual meeting. Moreover, the drug zenocutuzumab, which targets the NRG1 receptor that drives pancreatic cancer progression, showed additional benefit in a subgroup of patients based on specific biomarkers.
The repurposed use of this medication for treating cancer is a new approach to fighting the disease. It has been shown that this medicine can stop the growth of cancer cells and can increase the effectiveness of other treatments. It works by interfering with the function of the microtubules in the cancer cell. This helps to starve the cell of glucose, which is what most cancers rely on for energy.
There is also evidence that this drug can help fight tumors by interfering with the cell’s cellular signaling. This can lead to the death of cancer cells without affecting healthy cells. It is thought that this effect can be achieved by combining this drug with other medicines that target specific cellular signals.
One case study involved a woman with stage four lung cancer who took oral fenbendazole. Her CEA levels were rising, and her family was worried about the progression of her disease. She had seen YouTube videos from Joe Tippens, who claimed that fenbendazole was an effective cancer treatment. Initially, she was skeptical of the claims, but she decided to try it out.
After a few weeks, she began to notice that her tumors were shrinking. In addition to taking fenbendazole, she also started taking quercetin. This herb is not harmful to healthy cells and has been shown to be effective against several types of cancers. It can also boost the production of a gene known as p53, which can help keep cancer cells in check.
This medication is available at some health food stores and pharmacies. It is also sold by online retailers such as Safeguard and Happy Healing. These websites offer a range of different brands of the drug, and they all have third-party lab results to show for it. In addition, these sites are regulated to protect their customers from fake products.
Fenbendazole, more commonly known as FenBen, is a broad-spectrum anthelmintic in the family of benzimidazole carbamate anthelmintics that has been safely used for worm infections for over six decades. It is effective against many different types of worm including the gastrointestinal nematode, hookworm and whipworm. It is a member of the benzimidazole carbamate class of anthelmintics that also includes albendazole and mebendazole. fenbendazole for pancreatic cancer
